ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2020
[Research progress of alpha-fetoprotein vaccine in hepatocellular carcinoma].
Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Hepatocellular carcinoma (HCC) is the fifth world's largest malignant tumor, which seriously endangers human health. The commonly used treatment effects are not satisfactory and the mortality rate is still high. Therefore, there is an urgent need for effective adjuvant treatment to improve patient survival. Alpha-fetoprotein (AFP) acts as the most common tumor marker used for HCC diagnosis. Studies have shown that alpha-fetoprotein can self-induce T cells in patients with hepatocellular carcinoma, and its immunogenic antigenic epitopes provide new ideas for the study of AFP vaccine. Presently, a variety of AFP vaccines have been developed, such as DC vaccine, DNA vaccine, and peptide vaccine, which have been successfully applied to HCC mouse model and phase I /II clinical trials, with evident results. This article discusses the molecular mechanism, categories and application prospects of AFP vaccine in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.